The immunotherapy agent atezolizumab, marketed as Tecentriq, combined with the immunotherapy regimen albumin-bound paclitaxel or nab-paclitaxel, branded as Abraxane, received approval for the treatment of unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer [28]. The gene discussed is CD274; the disease is breast carcinoma.